Cisplatin nephrotoxicity: A review

被引:940
作者
Yao, Xin [1 ]
Panichpisal, Kessarin [1 ]
Kurtzman, Neil [1 ]
Nugent, Kenneth [1 ]
机构
[1] Texas Tech Univ, Hlth Sci Ctr, Dept Internal Med, Lubbock, TX 79430 USA
关键词
cisplatin; toxicity; acute renal insufficiency; apoptosis; reactive oxygen species;
D O I
10.1097/MAJ.0b013e31812dfe1e
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Background: Cisplatin is a major antineoplastic drug for the treatment of solid tumors, but it has dose-dependent renal toxicity. Methods: We reviewed clinical and experimental literature on cisplatin nephrotoxicity to identify new information on the mechanism of injury and potential approaches to prevention and/or treatment. Results: Unbound cisplatin is freely filtered at the glomerulus and taken up into renal tubular cells mainly by a transport-mediated process. The drug is at least partially metabolized into toxic species. Cisplatin has multiple intracellular effects, including regulating genes, causing direct cytotoxicity with reactive oxygen species, activating mitogen-activated protein kinases, inducing apoptosis, and stimulating inflammation and fibrogenesis. These events cause tubular damage and tubular dysfunction with sodium, potassium, and magnesium wasting. Most patients have a reversible decrease in glomerular filtration, but some have an irreversible decrease in glomerular filtration. Volume expansion and saline diuresis remain the most effective preventive strategies. Conclusions: Understanding the mechanisms of injury has led to multiple approaches to prevention. Furthermore, the experimental approaches in these studies with cisplatin are potentially applicable to other drugs causing renal dysfunction.
引用
收藏
页码:115 / 124
页数:10
相关论文
共 86 条
  • [31] MEK inhibitor, U0126, attenuates cisplatin-induced renal injury by decreasing inflammation and apoptosis
    Jo, SK
    Cho, WY
    Sung, SA
    Kim, HK
    Won, NH
    [J]. KIDNEY INTERNATIONAL, 2005, 67 (02) : 458 - 466
  • [32] CONTROL OF THE NEPHROTOXICITY OF CISPLATIN BY CLINICALLY USED SULFUR-CONTAINING-COMPOUNDS
    JONES, MM
    BASINGER, MA
    HOLSCHER, MA
    [J]. FUNDAMENTAL AND APPLIED TOXICOLOGY, 1992, 18 (02): : 181 - 188
  • [33] The effects of desferrioxamine on cisplatin-induced lipid peroxidation and the activities of antioxidant enzymes in rat kidneys
    Kadikoylu, G
    Bolaman, Z
    Demir, S
    Balkaya, M
    Akalin, N
    Enli, Y
    [J]. HUMAN & EXPERIMENTAL TOXICOLOGY, 2004, 23 (01) : 29 - 34
  • [34] Cisplatin nephrotoxicity and protection by milk thistle extract in rats
    Karimi, G
    Ramezani, M
    Tahoonian, Z
    [J]. EVIDENCE-BASED COMPLEMENTARY AND ALTERNATIVE MEDICINE, 2005, 2 (03) : 383 - 386
  • [35] Role and regulation of activation of caspases in cisplatin-induced injury to renal tubular epithelial cells
    Kaushal, GP
    Kaushal, V
    Hong, XM
    Shah, SV
    [J]. KIDNEY INTERNATIONAL, 2001, 60 (05) : 1726 - 1736
  • [36] Relationship of intracellular calcium and oxygen radicals to cisplatin-related renal cell injury
    Kawai, Y
    Nakao, T
    Kunimura, N
    Kohda, Y
    Gemba, M
    [J]. JOURNAL OF PHARMACOLOGICAL SCIENCES, 2006, 100 (01) : 65 - 72
  • [37] Anticancer drug-induced kidney disorders - Incidence, prevention and management
    Kintzel, PE
    [J]. DRUG SAFETY, 2001, 24 (01) : 19 - 38
  • [38] Serum thymic factor, FTS, attenuates cisplatin nephrotoxicity by suppressing cisplatin-induced ERK activation
    Kohda, Y
    Kawai, Y
    Iwamoto, N
    Matsunaga, Y
    Aiga, H
    Awaya, A
    Gemba, M
    [J]. BIOCHEMICAL PHARMACOLOGY, 2005, 70 (09) : 1408 - 1416
  • [39] Kollmannsberger C, 1999, SEMIN SURG ONCOL, V17, P275, DOI 10.1002/(SICI)1098-2388(199912)17:4<275::AID-SSU9>3.0.CO
  • [40] 2-U